• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173179 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  7 p0 J6 Z0 ~, ]5 |6 Z2 }3 B$ f
: r0 u. ^, ~  G! ^

; i0 f9 O. T. e8 uSub-category:
+ C9 n4 J0 S) P* P  c! u5 }Molecular Targets
7 z& M. b, w' C8 \
" h# z' W- b" R
  b; F: p4 t# n0 }+ P3 |3 GCategory:# w$ R" L' g( b: @
Tumor Biology
; p/ n, z8 C0 d/ _6 `' L7 m. V6 {. s: _% [( _

! p) p4 T# `. X3 q4 D. T4 jMeeting:' ?. U7 D3 L, Z) t6 R! f
2011 ASCO Annual Meeting
/ M4 h" [" W! N) k, P/ r
% O! r0 Y( `& N7 d; J& e' t- l6 Z% u- Y4 h, I8 c8 v2 R! N' T/ p7 u
Session Type and Session Title:0 `% F  k& [( k9 }
Poster Discussion Session, Tumor Biology " Y# O6 H% i2 u, T4 O

- U! M0 g5 G1 T8 s  W1 F% Z# k
/ y; U* N+ R" s# L8 FAbstract No:
! |# U# J( K/ Y6 U8 I# H9 s10517
; {& E' m/ O0 [4 e0 Y
. d# m: g! Z+ g  }0 r4 ]& J5 X
4 y. J& V' U: K1 d: ]9 C' P0 ICitation:# [+ k! h! c9 I4 [+ a* ]* u$ J9 }. L
J Clin Oncol 29: 2011 (suppl; abstr 10517)
  b8 ^( ]3 i2 \, r
3 a# B5 x8 M' k  `% I
; A" B% e. k7 Z' Q4 ~$ zAuthor(s):
& |- k1 e" s' S  @J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 K2 j) R+ k2 `7 B. {, W5 {4 c; e) L# \7 D5 T' B/ z; D

1 k2 a9 E1 m" }' @1 y  C
- o! R% W0 C8 G6 y( _Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 f. U+ {3 T6 O( e0 x  v
: e3 ?% q0 u+ Z8 v  z/ `8 r+ gAbstract Disclosures
% }5 a, s4 Z( S" }% y+ g% @" [4 Q( B' C2 g4 z# r0 O/ V
Abstract:" V. L: ]7 ]- }3 D) }) {2 E; G
# x' O# v) C0 p! v, o0 J
  b2 X- [& P1 x' `/ S9 |: t$ o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; X9 X$ A5 Q& u& e

0 n6 S/ Z/ @' j- O5 k8 q; Q4 O4 a 0 l0 r7 e% ?7 b( J
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 + I, ^* N. `, J6 [! \
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
1 s3 L5 ^" ~* a8 K
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ' p3 }# ?4 T3 q
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。0 W( |& P1 r2 b2 W
ALK一个指标医院要900多 ...
, X) Y! v7 `  i5 G1 j& {+ a
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?( M9 G& p: E' y: l1 v' A4 r/ u# }

5 A; N0 b6 T; D0 S现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表